CLINICAL_TRIALS ClinicalTrials.gov record update

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06790706
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:12.651195+00:00
Published At: 2025-10-06T00:00:00+00:00
Record Updated At: 2025-10-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Peritoneal Mesothelioma", "Gestational Trophoblastic Tumor", "Thymoma and Thymic Carcinoma", "Anaplastic Thyroid Carcinomas", "Gastroenteropancreatic Neuroendocrine Tumor", "Carcinoid Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-10-06"
protocolSection.identificationModule.nctId: "NCT06790706"
protocolSection.identificationModule.officialTitle: "IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.